Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Ncardia and BlueRock Form Collaboration | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Ncardia and BlueRock Form Collaboration

Agreement and licensing of process development technologies for the manufacture of iPSC-derived cardiomyocytes.

By: Tiffany Coppolino

Ncardia and BlueRock Therapeutics have entered an agreement covering process development technologies for the manufacture of induced pluripotent stem cell (iPSC)-derived cardiomyocytes. Bluerock gains access to Ncardia’s large-scale production processes and intellectual property for the production of iPSC-derived cardiomyocytes for therapeutic use.
 
“BlueRock is a leader in the field of cell therapy and our collaboration is a perfect match of mission and capabilities,” said Stefan Braam, chief executive officer, Ncardia.This relationship allows us to utilize our experience in iPSC process development to help advance potential cell therapies for cardiac diseases.”
 
Emile Nuwaysir, president and chief executive officer, BlueRock Therapeutics, said, “There are hundreds of millions of people worldwide that suffer from degenerative cardiovascular disease where the root cause is the loss of healthy heart muscle cells, and where medical treatment options are limited. BlueRock’s authentic cellular therapy is a novel approach that has the potential to transform the lives of patients, but will require the manufacture of our cell therapies at unprecedented scale. The Ncardia team has developed key technologies related to this scale-up challenge, and we are pleased to work with them as we advance BlueRock’s novel CELL+GENE platform towards the clinic and those patients in need.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics